AI Terminal
ALLIANCE PHARMA PLC
Report Publication Announcement • Apr 12, 2022
7478_10-k_2022-04-12_44cd8e96-0980-496c-8612-4a21afa9c2b9.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 1058I
Alliance Pharma PLC
12 April 2022
| For immediate release | 12 April 2022 |
ALLIANCE PHARMA
("Alliance" or the "Group")
Posting of Annual Report and Notice of AGM
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the Annual Report and Accounts for the year ended 31 December 2021, and the notice of the 2022 AGM meeting to be held on 18 May, have now been posted to those shareholders who have opted out of receiving electronic communications from the Group.
Printed copies of the documents are also available by contacting Buchanan by email at [email protected] or by telephoning Buchanan on 020 7466 5000.
For further information:
| Alliance Pharma plc | + 44 (0)1249 466966 |
| Cora McCallum, Head of Investor Relations & Corporate Communications | + 44 (0)1249 705168 |
| [email protected] | |
| Buchanan | + 44 (0)20 7466 5000 |
| Mark Court / Sophie Wills / Hannah Ratcliff | |
| [email protected] | |
| Numis Securities Limited | + 44 (0)20 7260 1000 |
| Nominated Adviser: Freddie Barnfield / Duncan Monteith | |
| Corporate Broking: James Black | |
| Investec Bank plc | + 44 (0)20 7597 5970 |
| Corporate Finance: Daniel Adams | |
| Corporate Broking: Patrick Robb |
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.
Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.
Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ACSBKBBNFBKKNQD